Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

Clifford J. Bailey, Brian D. Green, Peter R. Flatt

Research output: Contribution to journalArticlepeer-review


Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalExpert Opinion on Investigational Drugs: authoritative analysis of r and d trends
Issue number8
Publication statusPublished - Aug 2010


  • Animals
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2
  • Dipeptidyl-Peptidase IV Inhibitors
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypoglycemia
  • Hypoglycemic Agents
  • Insulin Resistance
  • Male
  • Pyrazines
  • Thiazolidinediones
  • Triazoles


Dive into the research topics of 'Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone'. Together they form a unique fingerprint.

Cite this